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Abstract
Background—The Infant Study of Inhaled Saline (ISIS) in CF was the first multicenter clinical 
trial to utilize infant pulmonary function tests (iPFTs) as an endpoint.
Methods—Secondary analysis of ISIS data was conducted in order to assess feasibility of iPFT 
measures and their associations with respiratory symptoms. Standard deviations were calculated to 
aid in power calculations for future clinical trials.
Corresponding Author and Address: Stephanie D Davis MD; Indiana University of Medicine, Riley Hospital for Children, 705 Riley 
Hospital Dr. ROC 4270; Indianapolis, IN 46202-5225
*During the conduct of this study, Dr. Davis was a faculty member in the Department of Pediatrics, Division of Pediatric 
Pulmonology, and University of North Carolina at Chapel Hill
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our 
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of 
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be 
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
HHS Public Access
Author manuscript
J Cyst Fibros. Author manuscript; available in PMC 2017 May 01.
Published in final edited form as:
J Cyst Fibros. 2016 May ; 15(3): 386–391. doi:10.1016/j.jcf.2015.10.007.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Results—73 participants enrolled, 70 returned for the final visit; 62 (89%) and 45 (64%) had 
acceptable paired functional residual volume (FRC) and raised volume measurements, 
respectively. Mean baseline FEV0.5, FEF75 and FRC z-scores were 0.3 (SD: 1.2), −0.2 (SD: 2.0) 
and 1.8 (SD: 2.0).
Conclusions—iPFTs are not appropriate primary endpoints for multicenter clinical trials due to 
challenges of obtaining acceptable data and near-normal average raised volume measurements. 
Raised volume measures have potential to serve as secondary endpoints in future clinical CF trials.
INTRODUCTION
Cystic fibrosis (CF) lung disease begins early and frequently prior to the onset of symptoms 
(1–6). Thus, chronic therapies may be most effective if initiated during infancy, in order to 
delay or prevent irreversible airway damage. This hypothesis is particularly important to test 
in the current era of cystic fibrosis transmembrane conductance regulator (CFTR) modulator 
therapy development. Unfortunately, the lack of well-developed and validated clinical trial 
endpoints in infants with CF has hindered the conduct of interventional studies in this age 
range. In infants with CF, early lung function abnormalities (diminished forced expiratory 
flows and gas trapping) have been demonstrated that could potentially be improved by 
therapeutic interventions (3–7). In preschool and school age children, the lung clearance 
index (LCI) measured by multiple breath washout is emerging as an exciting clinical trial 
endpoint, as it is clearly more sensitive than spirometry to early disease in this age range (8, 
9). In some infants with CF who have normal forced expiratory flows, LCI is abnormal; 
however, in others, LCI is normal, despite abnormal forced expiratory flows (10). These 
findings suggest that forced expiratory flows and LCI are measuring different aspects of CF 
airway pathophysiology. Further, technical issues currently preclude the use of multiple 
breath washout as a multicenter clinical trial endpoint in infants. Thus, there is continued 
interest in lung function testing using the raised volume rapid thoracic compression 
(RVRTC) technique combined with plethysmography in clinical trials in infants with CF.(7, 
11)
A recent multicenter clinical trial, the Infant Study of Inhaled Saline (ISIS) in CF, revealed 
that hypertonic saline inhaled twice daily for 48 weeks did not reduce the rate of pulmonary 
exacerbations in children <6 years of age (7), in contrast to the results of previous studies in 
older participants with CF (12). In a sub-study at selected sites, infant pulmonary function 
tests (infant PFTs: RVRTC and plethysmography) were evaluated as an exploratory 
endpoint. As previously reported, there was a treatment effect of hypertonic saline on the 
forced expiratory volume in 0.5 seconds (FEV0.5), though the clinical significance of this 
finding is unknown (7).
While these results support the potential of infant PFTs as outcome measures for 
interventional trials, the initial analysis was limited to the assessment of treatment effects. 
As the ISIS trial was the first multicenter clinical trial to utilize infant PFTs as an endpoint, 
it provides a unique opportunity to evaluate the feasibility and utility of these tests as 
endpoints for future clinical trials. Thus, the objectives of the current analyses were to (1) 
evaluate the feasibility of repeated infant PFTs in the multicenter clinical trial setting; (2) 
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provide standard deviations to aid in power calculations for future clinical trials; and (3) 
assess the associations between infant PFT measures and parent report of respiratory 
symptoms, as measured by the Respiratory Symptom Scale of the Cystic Fibrosis 
Questionnaire-Revised (CFQ-R), the most widely used disease-specific health related 
quality of life instrument for CF. Portions of this work have been published in abstract form 
(13).
METHODS
This is a secondary analysis of data from the ISIS trial (7). In brief, the ISIS trial was a 30-
center randomized controlled trial comparing 7% hypertonic saline (active drug) to 0.9% 
isotonic saline (control) inhaled twice a day for 48 weeks in children 4 to 60 months of age 
with CF. A sub-study evaluating infant PFTs as an exploratory endpoint was performed in 
infants 4 to 15 months of age at enrollment at 15 sites. Institutional review board approval 
was obtained at each center and informed consent was signed by the parent or guardian of 
each participant. As previously described (7), participants underwent plethysmography (14, 
15) (yielding measurement of functional residual capacity, FRC) and measurement of forced 
expiratory flows and volumes by the RVRTC technique (16, 17) (yielding measurement of 
FEV0.5; forced expiratory flows at 75% of forced vital capacity (FVC), FEF75 and forced 
expiratory flows between 25 and 75% of FVC, FEF25–75) at enrollment and the final study 
visit. Four sites also performed an additional infant PFT at the 4 week visit to evaluate 
potential early treatment effects.
Participating sites were trained and certified in research-quality infant PFTs. All sites used 
the Infant Pulmonary Laboratory (nSpire Health, Longmont, CO, USA) device and a study-
specific standard operating procedure. Infant PFT data were transferred to the Therapeutics 
Development Network Infant PFT Resource Center at the University of North Carolina for 
expert over-reading. The Resource Center reviewed all PFT data from each site for 
identification of research-quality measurements for inclusion in the final analysis database 
and for quality assessment. Research-quality measurements were chosen from the raw data 
according to published guidelines (14, 16).
The CFQ-R Parent Report was administered at enrollment, 12, 24, 36 and 48 weeks. 
Responses were standardized from 0–100, with higher scores indicating better health-related 
quality of life (18). For purposes of this analysis, only the Respiratory Symptoms Scale 
score (6 items) at enrollment and 48 weeks was utilized.
Statistical Analysis
The feasibility of infant PFTs was described by numbers of participants who consented to 
the PFT sub-study, came to the study visit, initiated the PFT procedures, and had research-
quality measurements. The probability of having acceptable measures at both baseline and 
48 weeks was evaluated by logistic regression. The associations between each PFT 
parameter (FEV0.5, FEF75, FEF25–75, FRC) and the CFQ-R Respiratory Symptoms Scale 
score at baseline, and between change in each PFT parameter and the change in CFQ-R 
Respiratory Symptoms Scale score over 48 weeks, were evaluated by linear regression. The 
estimated standard deviations in the 48-week change in each PFT parameter for both arms 
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combined, adjusted for baseline PFT parameter, gender, age, height, and weight, are reported 
to aid in sample size calculations for future clinical trials. P-values less than 0.05 were 
considered statistically significant.
RESULTS
Infant PFT feasibility and characteristics of the cohort
Of the total 321 participants in the ISIS study, 73 participated in the Infant PFT substudy. 
Measurement feasibility is shown in Table 1. All 73 participants initiated plethysmography 
and 72 initiated RVRTC at the baseline visit; 1 participant did not initiate RVRTC due to 
sedation failure. Seventy participants (96%) returned for the final study visit. Of these 
participants, 7 (10%) did not complete testing: 2 failed sedation and 5 met exclusion criteria 
for infant PFTs or exclusion criteria were not adequately assessed. FRC measurements were 
successful in 73/73 (100%) of participants at baseline, 62/70 (89%) at 48 weeks and 62/70 
(89%) at both visits. RVRTC measurements were successful in 61/73 (84%) at baseline, 
49/70 (70%) at 48 weeks and 45/70 (64%) at both visits. Feasibility of expiratory reserve 
volume (ERV) was lower (36 or 51%) at both visits because ERV calculation requires 
acceptable measurements of both FRC and RVRTC.
Baseline characteristics of the cohort are shown in Table 2. Among infants with acceptable 
RVRTC measurements at baseline and at 48 weeks, median weight percentile was 22.5 (IQR 
11, 50.5) and mean FEV0.5, FEF75, FEF25–75, and FRC z scores were 0.3 (SD 1.2), −0.2 (SD 
2.0), 0.2 (SD 1.4), and 1.8 (SD 2.0), respectively. The characteristics of infants with two 
acceptable RVRTC measurements were generally similar to those without two acceptable 
measurements, although two acceptable measurements were more likely among participants 
with higher baseline FEV0.5 z-scores (odds ratio (OR) per 1 higher z-score: 1.8; 95% CI: 
1.7, 5.9); and less likely among participants with higher baseline RV/TLC (OR per 1% 
higher value: 0.89; 95% CI: 0.80, 0.98) or higher baseline CFQ-R respiratory score (OR per 
1 higher score: 0.92; 95% CI: 0.85,0.98).
Among the infants in whom measurements were obtained but were not of research quality, 
reasons for failing to meet acceptability criteria are detailed in Table 3. The most common 
reasons for unacceptable RVRTC measurements were lack of flow limitation and lack of two 
technically acceptable curves with indices within 10% of one another. The most common 
reasons for unacceptable ERV measurements were tidal breathing data not collected for at 
least 15 seconds prior to inflation and lack of at least 2 to 3 acceptable measurements within 
10% of one another. (The ERV criteria for acceptability was established specifically for this 
study since guidelines for this measurement have not been published.)
Infant lung function measurements for participants in the 4 week visit
Eighteen participants completed the additional 4-week infant PFT visit. Among the 11 
participants (6 randomized to hypertonic saline and 5 to isotonic saline) with acceptable 
measurements at enrollment, 4 weeks and 48 weeks, the mean 4-week change in FEV0.5 
(adjusted for baseline FEV0.5, gender, age, height and weight) was 34 ml (95% CI: −108, 
176) greater among those randomized to hypertonic saline. Among those same 11 
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participants, the mean 48-week change in FEV0.5 was 59 ml (95% CI: −72, 190) greater 
among those randomized to hypertonic saline. (For comparison, among all 45 infant PFT 
substudy participants with acceptable measurements at enrollment and 48 weeks, the 
adjusted mean 48-week change in FEV0.5 was 38 ml (95% CI 1, 76) (7) greater among those 
randomized to hypertonic saline (7).)
Comparison of Infant lung function and parent-reported respiratory symptoms
We evaluated the association of lung function measures with the CFQ-R Respiratory 
Symptom Scale score both cross-sectionally at enrollment and longitudinally over the study 
period (Table 4). At enrollment, there was a significant association between FRC and the 
Respiratory Symptom Scale score: for each 1 point higher (better) Respiratory Symptom 
Scale score, there was a mean 1.5 ml (95% CI: 0.5, 2.6) lower (better) FRC, adjusted for 
age, weight, height, and gender; p =0.007. None of the other cross-sectional or longitudinal 
associations between PFT measures and the CFQ-R Respiratory Symptom Scale score were 
statistically significant.
Sample size planning for future clinical trials
Anticipated treatment effects in future clinical trials will be intervention-specific and not 
necessarily informed by the results of the ISIS trial However, the standard deviation of the 
48-week change in the PFT parameters observed in the ISIS trial can be used to aid in 
sample size calculations for future trials. For FEV0.5, the estimated standard deviation 
adjusted for baseline PFT parameter, gender, age, height and weight was 63 ml, for FEF75 
119 ml/s, for FEF25–75 174 ml/s, for FRC 58 ml and for RV/TLC 5%.
DISCUSSION
In this secondary analysis of the ISIS infant pulmonary function sub-study, we assessed the 
feasibility and utility of various lung function parameters as endpoints in future clinical 
trials. Among the PFT parameters evaluated, the measurement acceptability rate for FRC 
was the highest but a significant treatment effect was not detected in the ISIS trial (7). Thus, 
FRC appears unlikely to be an appropriate clinical trial endpoint for future studies of drugs 
with a similar mechanism of action to hypertonic saline. There was a significant treatment 
effect detected with the RVRTC measurement FEV0.5, but the proportion of acceptable 
measurements was low; only 64% of infants had two acceptable measurements. Missing data 
can lead to problems with efficiency and bias. Indeed, infants with and without two 
acceptable measurements were not comparable: two acceptable measurements were more 
likely among participants with higher baseline FEV0.5 z-scores, lower RV/TLC values, and 
lower CFQ-R scores. Finally, average lung function at baseline was normal or near normal 
for most infant PFT parameters, making it more difficult to detect a treatment effect.
While we found no evidence that demographic characteristics such as age or gender were 
associated with feasibility of infant PFTs, we did observe a difference in feasibility based on 
baseline lung function, in that infants with less airway obstruction (higher FEV0.5 and lower 
RV/TLC) were more likely to have two acceptable measurements. Though preliminary, this 
observation suggests that bias could be introduced by missing data. Future investigators may 
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wish to assess the comparability of baseline lung function between those with and without 
acceptable lung function measurements.
The centers that participated in this substudy were experienced in infant PFTs and many had 
participated in our previous multicenter infant PFT study (6). In addition, the Infant PFT 
Resource Center provided rigorous training and certification to all sites as well as ongoing 
quality control and feedback. Despite this, feasibility was only fair, highlighting the 
importance of intensive education for infant PFT personnel. Feasibility of the RVRTC 
measurements may have been influenced by the sequence of measurements, as 
plethysmography was always conducted first. However, given that the RVRTC maneuver 
may influence FRC values, FRC measurements need to be performed first.
To better understand the feasibility of infant PFTs, acceptability criteria were evaluated for 
each study performed across the 15 sites (Table 3). The acceptability of plethysmography 
was quite high. For the RVRTC technique, the main reasons for lack of acceptability were 
inability to achieve flow limitation and lack of two technically acceptable curves with 
indices within 10% of one another. Based on our findings, the concept of flow limitation 
should be emphasized in training sessions. ERV acceptability was even lower than that of 
RVRTC. The main reasons were failure to collect tidal breathing data for at least 15 seconds 
prior to inflation and failure to collect a minimum of 2 to 3 acceptable ERV measures within 
10% of each other. However, there are no published guidelines for ERV and the ISIS criteria 
may have been too stringent. More studies are needed to better understand how current ERV 
acceptability criteria influence measurement results.
In order to determine an appropriate sample size for future clinical trials, estimates of the 
standard deviation of the outcome measure as well as the anticipated treatment effect are 
necessary. We therefore have included the standard deviation of the 48-week change in the 
PFT measures among the ISIS infant PFT sub-study participants. Anticipating treatment 
effects for future studies will be challenging, as there is currently no minimal clinically 
important difference (MCID) for infant PFT parameters. The clinical significance of the 
treatment effect observed with FEV0.5 in the ISIS trial is not known. Future studies relating 
change in infant PFT parameters to changes in respiratory symptoms, PFTs at school age or 
other outcomes may help to begin to establish a MCID for these parameters.
Indeed, we did conduct an exploratory evaluation of the association of lung function with 
parent-reported respiratory symptoms: a lower (better) FRC value at baseline was associated 
with a higher (better) Respiratory Symptom Scale of the Cystic Fibrosis Questionnaire-
Revised (CFQ-R)) score. Other infant lung function indices were not associated with 
parental report of respiratory symptoms. These results suggest that parental perception of 
respiratory symptoms may reflect physiologic changes consistent with obstructive lung 
disease but are not clearly helpful for determining the MCID for FRC. We previously 
reported in the entire ISIS cohort that worse CFQ-R respiratory symptom scores and 
physical functioning scores were associated with an increase in pulmonary exacerbation rate 
(19) and that parents were astute at reporting symptoms in young children with CF (20).
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In the small subset of participants that participated in the 4-week infant PFTs, a treatment 
effect was not seen at 4 or 48 weeks, likely due to the small sample size (N=11). At 4 weeks, 
the mean (unadjusted) change for those randomized to hypertonic saline was 7.8 ml and the 
mean (unadjusted) change for those randomized to isotonic saline (control agent) was −11 
ml. As expected, the 1 month change in forced expiratory volumes and flows predicted the 
final change in these lung function indices at 48 weeks (data not presented). In the 
Australian hypertonic saline study in older children and adults (12), a response in lung 
function was seen within 4 weeks and plateaued over the 48 week treatment period in those 
receiving hypertonic saline therapy. In the ISIS trial, a larger sample size might have helped 
to discriminate responders versus non-responders at this early time point. An improved 
understanding of responders within 4 weeks would certainly be beneficial during the infant 
and preschool years when adherence to therapy may be suboptimal.
Infant PFTs have historically been demonstrated to be abnormal in both conventionally-
diagnosed and newborn-screened infant cohorts in Australia, and the UK (1, 3, 4, 10). In 
contrast, in our study the mean baseline RVRTC parameters were normal to near normal as 
highlighted in the baseline z-scores. Recently, near normal lung function was also reported 
in a newborn-screened infant cohort from the UK (21), which was in contrast to previous 
UK reports in infants diagnosed clinically. (3, 22) The measurement techniques were 
relatively similar in all these studies. It is unclear whether these differences in reported 
infant PFT results are due to different measurement devices, reference equations or true 
biologic and/or treatment differences.
Existing published reference equations for infant lung function have important limitations, 
including small sample sizes and possible differences in technique or devices. In the U.S., 
sedating healthy infants for the purpose of obtaining normative data is often not allowed, so 
contemporaneous controls cannot be obtained. We only utilized z scores to describe the 
baseline characteristics of our cohort. When evaluating a therapeutic response, we strongly 
recommend the use of raw values adjusted for weight, height, age, gender and baseline lung 
function, as was done in this trial.
While the lung clearance index as measured by multiple breath washout has clearly been 
shown to detect lung disease with greater sensitivity than spirometry in preschool and 
school-age CF patients (8, 9), in the infant population, multiple breath washout does not 
appear to be more sensitive to disease than RVRTC/plethysmography (10) and is indeed 
frequently in the normal range (23). Further, though abnormalities in RVRTC and MBW 
indices have been reported in the same infants with CF diagnosed clinically (3, 22), these 
two measurement abnormalities also differed in other infants, suggesting that these tests may 
be complimentary. Thus, there is not currently a physiologic endpoint in infants that is 
clearly superior; each technique has its pros and cons. The ISIS multiple breath washout 
substudy also found LCI to be normal in infants at baseline with worsening over time 
observed in the isotonic saline group. (23) Thus, for both the raised volume technique and 
multiple breath washout, maintaining lung function that is normal at baseline may be the 
more suitable outcome. It is likely that a multimodal approach assessing more than one 
outcome measure will be most suitable in evaluating treatment efficacy in infants with CF.
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In conclusion, infant PFTs do not appear to be appropriate primary endpoints for multicenter 
clinical trials due to the near normal average raised volume measurements in infants with CF 
and the challenges of obtaining acceptable data. However, given that an effect of hypertonic 
saline on FEV0.5 was detected in the ISIS study (7) and improvements in feasibility may be 
possible, infant PFTs may be useful as secondary endpoints in selected future clinical CF 
trials.
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Highlights
• We evaluated infant lung function as a clinical trial endpoint in cystic fibrosis.
• Challenges included obtaining feasible raised volume data across multiple sites.
• Infant lung function tests may be useful as secondary outcomes measures.
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Table 1
Feasibility of Infant Pulmonary Function Testing
Baseline n (%)1 48 weeks n (%)1 Baseline and 48 weeks n (%)1
Consented to testing 73 73 73
Returned for visit 73 70 70
Initiated plethysmography 73 64 64
Initiated RVRTC2 72 63 63
FRC3
Acceptable 73 (100%) 62 (88.6%) 62 (88.6%)
RVRTC2
Acceptable 61 (83.6%) 49 (70.0%) 45 (64.3%)
ERV4
Acceptable 56 (76.7%) 43 (61.4%) 36 (51.4%)
1
The denominators used for percentages are the number of participants who returned for testing at each visit.
2
RVRTC, raised volume rapid thoracic compression
3
FRC, functional residual capacity, measured by plethysmography
4
ERV, expiratory reserve volume. Requires acceptable RVRTC and plethysmography; needed to calculate fractional lung volumes.
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Table 2
Baseline participant characteristics of the 73 participants enrolled in the ISIS infant PFT substudy
With acceptable RVRTC measures at baseline 
and 48 weeks
N=45
Without acceptable RVRTC measures at baseline 
and 48 weeks
N=28
% or mean (standard deviation)*
Treatment assignment
 % Hypertonic Saline (HS) 49% 50%
Age (months) 9.0 (3.4) 10.2 (3.4)
Gender (% male) 55% 50%
Genotype1
 F508del Homozygous 53% 50%
 F508del Heterozygous 42% 32%
 Other 4% 18%
Weight, kg* 8.1 (7.5, 9.6) 8.4 (7.4, 10.2)
Weight percentile* 22.5 (11, 50.5) 28.0 (10.4, 54.8)
Height, cm* 68.9 (66, 72.4) 70.7 (64.5, 73.5)
Height percentile* 28.7 (7.9, 45.5) 16.2 (5.7, 28.6)
FEV0.5. ml 284 (65) 266. (71)2
FEV0.5 z-score3 0.3 (1.2) −0.6 (1.3)2
FEF75, ml/sec 298 (119) 280 (116) 2
FEF75, z-score −0.2 (2.0) 2.0 (2.1)
FEF 25–75, ml/sec 595 (191) 556 (194) 2
FEF 25–75, z-score 0.2 (1.4) −0.4 (1.6)
FRC, ml 204 (52) 211 (60)
FRC, z-score4 1.8 (2.0) 2.0 (2.1)
RV/TLC, %5 27 (7) 33 (7)
CFQ-R respiratory score 87.5 (10.7) 93.8 (6.5)
*Weights and heights reported as medians with interquartile ranges.
1
Homozygous: F508del identified on both alleles; Heterozygous: F508del identified on one allele and mutation type for other allele either 
identified and not F508del, not identified, or not available.
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2N=16 participants with acceptable FEV0.5, FEF75, and FEF25–75 at baseline but not 48 weeks.
3
Z-scores based on reference equations with length for FEF75 and FEF25–75; and with length and age for FEV0.5 of Jones et al (18).
4
Z-scores for FRC were based on reference equations similar to those reported in Castile et al (15) but computed from a non-repeated measures 
subset of the control data (6) consistent with Jones et al (17)
5N=42 participants with acceptable RV/TLC at baseline and 48 weeks, and N=14 with acceptable RV/TLC at baseline but not 48 weeks
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Table 3
Infant PFT Acceptability
Criteria Not Met for Infant PFT Measurements Baseline Visit (N=73) 48 week Visit (N=70)
FRC
Total Measurements Not Acceptable 0 2
Box Signal Drift 1
Mouth pressure and box volume signals not in-phase 1
Minimum of 3 technically satisfactory FRC measurements not noted 2
RVRTC
Total Measurements Not Acceptable 11 13
Forced exhalation not complete (premature termination) 9 5
Sigh breath before forced exhalation 3 1
Lack of flow limitation 11 13
Glottic closure 7 5
Peak flow not achieved prior to exhalation of 10% of the volume 7 6
2 technically acceptable curves with indices within 10% of one another not noted 11 13
ERV
Total Measurements Not Acceptable 16 20
Tidal breathing data not collected for minimum of 15 seconds prior to inflation 1 20
Tidal breathing data not collected for minimum of 30 seconds post-forced exhalation 2 3
Minimum of 2 to 3 acceptable ERV measures within 10% of one another not noted 16 4
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Table 4
Cross-sectional and longitudinal associations between PFT measures and CFQ-R Respiratory Symptom Scale
Mean difference in PFT measure for one score 
higher CFQ-R respiratory score at enrollment
Mean 48 week change in PFT measure for one score 
higher change in CFQ-R respiratory score over 48 
weeks
Lung Function Measure N Mean (95% CI) N Mean (95% CI)
FEV0.5 (ml) 45 −0.1 (−1.5, 1.4) 43 1.0 (−0.6, 2.6)
FEF75 (ml/s) 45 1.4 (−2.0, 4.9) 43 1.7 (−1.6, 4.9)
FEF25–75 (ml/s) 45 3.1 (−2.1, 8.3) 43 3.9 (−0.8, 8.7)
FRC (ml) 45 −1.5 (−2.6, −0.5) 43 0.7 (−0.9, 2.3)
RV/TLC (%) 42 −0.1 (−0.4, 0.1) 35 −0.0 (−0.3, 0.2)
Models are adjusted for age, weight, height, and gender at baseline; the model of 48 week change also adjusts for treatment arm.
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